U.S. Rheumatoid Arthritis Therapeutics Market Size & Outlook
U.S. rheumatoid arthritis therapeutics market, 2018-2030 (US$M)
Related Markets
U.S. rheumatoid arthritis therapeutics market highlights
- The U.S. rheumatoid arthritis therapeutics market generated a revenue of USD 11,856.1 million in 2023 and is expected to reach USD 16,342.6 million by 2030.
- The U.S. market is expected to grow at a CAGR of 4.7% from 2024 to 2030.
- In terms of segment, biopharmaceuticals was the largest revenue generating molecule in 2023.
- Biopharmaceuticals is the most lucrative molecule segment registering the fastest growth during the forecast period.
Rheumatoid arthritis therapeutics market data book summary
| Market revenue in 2023 | USD 11,856.1 million |
| Market revenue in 2030 | USD 16,342.6 million |
| Growth rate | 4.7% (CAGR from 2023 to 2030) |
| Largest segment | Biopharmaceuticals |
| Fastest growing segment | Biopharmaceuticals |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pharmaceuticals, Biopharmaceuticals |
| Key market players worldwide | Boehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 47.4% of the global rheumatoid arthritis therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. rheumatoid arthritis therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 1,684.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Rheumatoid Arthritis Therapeutics Market Scope
Rheumatoid Arthritis Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. rheumatoid arthritis therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.
Biopharmaceuticals was the largest segment with a revenue share of 88.73% in 2023. Horizon Databook has segmented the U.S. rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. rheumatoid arthritis therapeutics market is witnessing significant developments and a positive growth trend, driven by product launches, approvals, and promising clinical trials. Recent advancements include the progress of Nipocalimab, an innovative antibody drug developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.
In November 2023, early results from a Phase 2a trial indicated that Nipocalimab could effectively decrease autoantibodies, including Anticitrullinated Protein Antibodies (ACPAs), which are prevalent in the blood of RA patients. The significance of this development lies in its potential to cater to a broader range of RA patients, addressing an urgent need for new therapeutic options.
In addition, the RA therapeutics market in the U.S. has been bolstered by the introduction of generic drugs that enhance accessibility and treatment options. For instance, in September 2020, pharmaceutical company Lupin launched a generic version of leflunomide, a drug used to manage symptoms of active RA. This introduction is likely to improve patient access to necessary treatments, contributing to market expansion.
Reasons to subscribe to U.S. rheumatoid arthritis therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. rheumatoid arthritis therapeutics market databook
-
Our clientele includes a mix of rheumatoid arthritis therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. rheumatoid arthritis therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into U.S. rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. rheumatoid arthritis therapeutics market size, by molecule, 2018-2030 (US$M)
U.S. Rheumatoid Arthritis Therapeutics Market Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
